ADCT

ADC TELECOMMUNICATIONS INC

ADCT

Overview Fund Activity

Delisted

ADCT was delisted on the 9th of December, 2010.

Back to rankings

Technology Communication Equipment

Financial journalist opinion

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland , Sept. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 29,700 of the Company's common shares to two new employees on September 2, 2025 (each, a "Grant").

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

LAUSANNE, Switzerland , Aug. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 9:10 a.m. ET. A webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com.

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

Zacks Investment Research

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.38 per share a year ago.

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates

ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript

ADC Therapeutics SA (NYSE:ADCT ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Ameet Mallik - CEO & Director Jose I. Carmona - Chief Financial Officer Mohamed Zaki - Chief Medical Officer Nicole Riley - Corporate Participant Conference Call Participants Eric Thomas Schmidt - Cantor Fitzgerald & Co., Research Division Jenna Li - Jefferies LLC, Research Division Leonid Timashev - RBC Capital Markets, Research Division Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division Sudan Naveen Loganathan - Stephens Inc., Research Division Operator Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics SA ADCT Q2 2025 Earnings Conference Call.

ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients Expansion to 100 r/r DLBCL patients underway in LOTIS-7 Phase 1b trial; Additional data to be shared in second half of 2025 LOTIS-5 Phase 3 trial expected to reach prespecified progression-free survival (PFS) events by end of 2025; update to follow once data are available Completed $100 million private placement extending expected cash runway into 2028 LAUSANNE, Switzerland , Aug. 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the second quarter ended June 30, 2025, and provided operational updates. "Entering the second half of 2025, we have streamlined our strategic focus and strengthened our financial foundation, which now allows us to pursue multiple promising opportunities to expand ZYNLONTA® into earlier lines of therapy in DLBCL and indolent lymphomas," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

LAUSANNE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates.

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

Zacks Investment Research

Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?

Here is how ADC Therapeutics SA (ADCT) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.

Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland , Aug. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 127,000 of the Company's common shares to three new employees on August 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

LAUSANNE, Switzerland , July 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,000 of the Company's common shares to one new employee on July 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69% CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatment ZYNLONTA was generally well tolerated and safety was consistent with known profile LAUSANNE, Switzerland , June 16, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA® to treat relapsed/refractory marginal zone lymphoma (r/r MZL) will be presented during a poster session at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20. These data will be made available online beginning on Wednesday, June 18, at 8:30 a.m.

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

See News Rankings

Charts implemented using Lightweight Charts™